title: Osteogenic response to hydroxyapatite-fibrin implants in maxillofacial bone defects.
abstract: Bone formation in hydroxyapatite-fibrin implants has been reported several times. However, available studies refer to experimental animals, or are limited to short periods after implantation. We report the results of histological, histochemical and ultrastructural studies carried out 2.5-8 yr after implantation of non-resorbable, porous hydroxyapatite (HA) and fibrin glue in human maxillofacial bones. Prominent ossification was found in all cases, with the presence of normally structured spongy bone. HA granules were embedded in the calcified bone matrix. They had not elicited inflammatory reactions and did not induce bone resorption. Ossification was preceded by the appearance of alkaline phosphatase activity on fibroblast-like cells, and by the formation of dense collagenous layers, similar to osteoid borders, on the surface of HA granules. The early phases of the calcification process occurred in these borders, with the appearance of calcification nodules adjacent to alkaline phosphatase-positive osteoblast-like cells. A remodeling process similar to that occurring in normal bones was found in the newly formed bone. These results justify the conclusion that HA-fibrin implants lead to the formation of long-lasting bone that does not differ from that of the normal maxillofacial skeleton. Mixing the HA granules with fibrin has the advantage of creating an easily mouldable material which can be adapted to any skeletal surface and stays in place after surgery.
authors.affiliation: Department of Experimental Medicine and Pathology, La Sapienza University, San Giovanni Hospital, Rome, Italy. bonucci@axrma.uniroma1.it
authors.forename: E
authors.initials: E
authors.lastname: Bonucci
authors.forename: E
authors.initials: E
authors.lastname: Marini
authors.forename: F
authors.initials: F
authors.lastname: Valdinucci
authors.forename: G
authors.initials: G
authors.lastname: Fortunato
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D001672:Biocompatible Materials; D001847:Bone Diseases / Q000201:enzymology / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D001857:Bone Matrix / Q000378:metabolism / Q000473:pathology; D016723:Bone Remodeling; D001862:Bone Resorption / Q000473:pathology; D002113:Calcification, Physiologic; D003094:Collagen / Q000378:metabolism; D017886:Durapatite; D005147:Facial Bones / Q000201:enzymology / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D015718:Fibrin Tissue Adhesive; D005347:Fibroblasts / Q000201:enzymology / Q000473:pathology; D005500:Follow-Up Studies; D006651:Histocytochemistry; D006801:Humans; D007249:Inflammation; D008854:Microscopy, Electron; D010006:Osteoblasts / Q000201:enzymology / Q000473:pathology; D010010:Osteoclasts / Q000473:pathology; D010012:Osteogenesis; D016062:Porosity; D019736:Prostheses and Implants; D014014:Tissue Adhesives
chemical_list: D001672:Biocompatible Materials; D015718:Fibrin Tissue Adhesive; D014014:Tissue Adhesives; D003094:Collagen; D017886:Durapatite; D000469:Alkaline Phosphatase